The Cystic Fibrosis Foundation (CFF) is investing up to $15.5 million in Anagram Therapeutics to conduct early-stage trials of a new oral enzyme replacement therapy. The company is planning to start a Phase 1 clinical trial this summer. The therapy would let people with cystic fibrosis (CF)…

Applications are being accepted for the Cystic Fibrosis Foundation‘s 2023 CFF Impact Grant program, which funds projects or programs to improve the lives of those with cystic fibrosis (CF) or their families. “The best ideas come from personal experience, and no one knows the ins and outs…

The Cystic Fibrosis Foundation’s 2022 CFF Impact Grant program is now accepting applications from individuals or nonprofit groups seeking funding for projects that support cystic fibrosis patients or their families in their everyday lives. Those wishing to develop such efforts — particularly virtual support programs — also may…

Out of 120 columns, my most controversial remains “Sugar Does the Trick, But I Won’t Let It Trick Me.” In the May 2018 piece, I critiqued the classic dietary advice that suggests people with cystic fibrosis should stack their diets with sugar to achieve rapid weight gain. I said…

Children and adolescents on Symdeko (tezacaftor/ivacaftor) and Orkambi (ivacaftor/lumacaftor) for cystic fibrosis (CF) had higher treatment adherence rates compared with adults given the same CFTR modulators, a nationwide study in the U.S. found. The study also showed that adherence — patients choosing to follow through with a prescribed treatment —…

The Cystic Fibrosis Foundation (CFF) awarded up to $3.75 million to Matinas BioPharma to support preclinical studies of MAT2501, a potential oral antibiotic to treat nontuberculous mycobacterium (NTM) infections in people with cystic fibrosis (CF) and other lung diseases. A goal of this early research work is…

Eloxx Pharmaceuticals is preparing to launch a Phase 2 clinical study in the U.S. to explore the potential of ELX-02 for treating people with cystic fibrosis (CF) who carry the G542X mutation. This follows approval by the U.S. Food and Drug Administration (FDA) of the…

The not-for-profit organization TB Alliance will receive up to $5.1 million from the Cystic Fibrosis Foundation (CFF) to advance the discovery and development of treatments for multidrug-resistant nontuberculous mycobacteria (NTM) infections in people with cystic fibrosis (CF). TB Alliance will partner with Johns Hopkins University over the next three years…